Researchers with BC Cancer have discovered a way to better predict treatment outcomes in patients with relapsed and refractory, or treatment-resistant, classic Hodgkin lymphoma.
A recent study conducted by TFRI-funded researchers at BC Cancer sheds light on the cause behind the different outcomes of patients with diffuse large B cell lymphoma (DLBCL) who experienced a relapse in their disease. The study confirmed that patients whose cancer relapses shortly after treatment typically have poor responses to additional chemotherapy-based treatment. However, when the relapse occurs more than two years from the time of diagnosis, the outcomes to chemotherapy are significantly better.
A recent study conducted by researchers at BC Cancer has shed light on the cause behind the different outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who experience a relapse of their disease. The study, led by Dr. Laura Hilton, staff scientist at BC Cancer’s Centre for Lymphoid Cancer (CLC), and Dr. David Scott, clinical director of the CLC, aimed to understand the molecular characteristics of the initial diagnostic and relapse tumour samples of patients with DLBCL.
The disease course for follicular lymphoma (FL) is highly variable, and while many patients respond to treatment, some may experience relapse or evolution of disease into a more aggressive form of lymphoma. By studying genetic mutations, gene and protein expression, and interactions between lymphoma cells and their environment, Dr. Scott’s LRF research aims to develop tools that can reliably predict patient outcomes and guide treatment decision-making.
The BCCF Innovation Support Fund Awardees are:
The BC Cancer Foundation, in partnership with BC Cancer, established the Innovation Support Fund competition in 2010 to enable the acquisition of equipment essential to conducting research.
It’s their fifth cycle of funding for researchers at the BC Cancer Centre for Lymphoid Cancer who are part of the renewal of a coveted Terry Fox New Frontiers Program Projects Grant, following the 2022 competition.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.